Needham Maintains Buy Rating for Intra-Cellular Therapies: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Needham has maintained its Buy rating for Intra-Cellular Therapies (NASDAQ:ITCI) and increased its price target from $70.00 to $73.00. Shares of Intra-Cellular Therapies have risen by 2.3% over the last 24 hours, trading at $64.94 per share. A move to $73.00 would represent a 12.41% increase from the current share price.
July 06, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham's maintained Buy rating and increased price target for Intra-Cellular Therapies could potentially boost investor confidence and drive the stock price up in the short term.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. Needham's decision to maintain a Buy rating and raise the price target for ITCI suggests a positive outlook for the company, which could potentially lead to an increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100